TTUHSC Welcome to the HSC
HomePaul L. Foster School of Medicine

Cancer Clinical Research Core Facility
440 Raynolds, El Paso, Tx79905
Phone: (915)793-1280
Fax: (915) 783-5208
 
 

OPEN CLINICAL TRIALS:

BREAST

“A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer” 

Eligible patients:  

Research type

For more information please contact:

 

“A Phase II, single arm study of the use of steroid-based mouthwash to prevent stomatitis in postmenopausal women with advanced or metastatic hormone receptor positive breast cancer being treated with everolimus plus exemestane”  

Eligible patients:  

Research type

For more information please contact:

 

INCB 18424-268:

"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer"

Eligible patients:  

Research type

For more information please contact:

SURVIVORSHIP CLINIC:

"Establishing and Testing a Breast Cancer Survivorship Program at TTUHSC-Paul L. Foster School of Medicine in El Paso
(Program #2)" – This study is testing the effectiveness of a comprehensive program which provides psychological and nutritional services for breast cancer survivors

Eligible patients: Breast cancer patients diagnosed after 2006 and treated at the GBCC, and who are not currently receiving
chemotherapy or radiation therapy.

Research type: survivorship care

For more information please contact:
Luis Sanchez 
luis.a.sanchez@ttuhsc.edu 
(915) 215-4812

VOCs:
"Development of a Novel Non-Invasive Diagnostic Method for Early Detection of Breast Cancer Using Cancer Specific Volatile Organic Compounds (VOCs) in Urine" - The goal of this research is to develop a method to identify cancer specific components in urine so that we can use those components as markers to detect breast cancer
 
Eligible patients: any patient with newly diagnosed breast cancer, any stage , before receiving surgery or other cancer treatment
 
Research type: exploratory
 
For more information please contact:
NOVARTIS:

“A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment.” - This protocol will test the benefit of adding a new drug to standard treatment for patients with advanced breast cancer

Eligible patients: breast cancer patients, stage IV, whose cancer has progressed on exemstane and everolimus

Research type: therapeutic

For more information please contact:

METABOLIC SYNDROME:

"Effect of chemotherapy on markers of metabolic syndrome in early breast cancer" - The purpose of this protocol is to find out if chemotherapy places a patient at a greater risk for metabolic syndrome by assessing for important markers (weight, waist circumference, body mass index, blood pressure, glucose levels, insulin levels, triglycerides and HDL cholesterol)

Eligible patients: Breast cancer patients planning to start chemotherapy for early (nonmetastatic) breast cancer

Research type: supportive care 

For more information please contact:

BRCA1-BRCA2:

"BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects" - This research study is sponsored by the National Institute of Health and aims at assessing BRCA mutations in Hispanic/Latinas with breast cancer

Eligible patients: any breast cancer patients of Hispanic/Latina descent

Research type:  exploratory

For more information please contact:

Neulasta:

"Randomized, single-blind study to estimate the effect of patient education on reported bone pain in breast cancer patients receiving chemotherapy and pegfilgrastim" 

Summary: “The purpose of this study is to learn more about whether viewing an educational DVD can affect reported bone pain in  breast cancer patients who are being treated with chemotherapy and Neulasta®. Neulasta® is used to help prevent decreased white cell count and  strengthen a patient’s immune system during chemotherapy, but a side-effect of this medication is bone pain” 

Eligible patientsBreast cancer patients planning to start chemotherapy (nonmetastatic, English speaking) 

Research type: supportive care 

For more information please contact:

SWOG 1007:

"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and Her2-Negative Breast Cancer according to Recurrence Score (RS)" - This research protocol is for patients with node-positive, hormone-receptor positive, HER2 negative breast cancer who also have node-positive breast cancer. The purpose of this study is to use a test to predict who will benefit from chemotherapy and who is unlikely to benefit so that we can save some patients from the serious side effects and the cost of a course of chemotherapy treatment they don’t need

Eligible patients: Patients with breast cancer,node positive, Estrogen or progesterone receptor positive and Her2 neu negative , nonmetastatic 

Research type: supportive care 

For more information please contact:

SWOG 1202:

"A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer"The purpose of this research study to find out if duloxetine may lessen muscle, bone, and joint pain caused by anti-hormone therapy (aromatase inhibitors)

Eligible patients: Patients with breast cancer,node positive, Estrogen or progesterone receptor positive and Her2 neu negative , nonmetastatic 

Research type: therapeutic

For more information please contact:

SWOG 1207:

"A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer" - This research study is for patients who have hormone-receptor-positive breast cancer that is HER2-negative. The aim is to find out whether the drug everolimus (Affinitor®) taken with hormonal therapy is even more effective than standard hormonal therapy for patients with breast cancer who have a high risk for cancer recurrence

Eligible patients: English speaking patients

Research type

For more information please contact:

SPOC TISSUE BANK:

"Banking of Tissue and Establishing Continuous Cell Lines and Xenografts from Neoplasia" - 5000 patients approved for enrollment; 198 enrolled patients

Eligible patients:  

Research type

For more information please contact:

 LIVER CANCER:
 

CTSU CALGB-80802:

"Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)" - This is a study for patients with Advanced Hepatocellular Carcinoma (HCC). The purpose of this study is to further prove that the combination of sorafenib and doxorubicin could improve outcomes for patients with HCC. So far it represents the only therapy that suggests an improvement in survival beyond the one year based on the trandomized phase II study. This is critically important as we continue to combat the increasingly prevalent and deadly HCC

Eligible patients:  

Research type

For more information please contact:

PANCREATIC CANCER:

“A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine Pancreatic study” 

Eligible patients:  

Research type

For more information please contact:

CLOSED CLINICAL TRIALS:

SWOG 0221:

“Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer."   

Eligible patients:  

Research type

For more information please contact:

 

SWOG 0927:

"A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III" 

Eligible patients:  

Research type

For more information please contact:

 

"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbapoetin Alfa Administered at 500 micro-grams Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy." 

Eligible patients:  

Research type

For more information please contact:

 

 

 

 

 

 

 

 

 

 

 

©